Updated:
Abiomed
Abiomed® is committed to leading in technology and innovation, and improving patient outcomes by developing smaller, smarter and more connected technology.
Abiomed
Abiomed® is committed to leading in technology and innovation, and improving patient outcomes by developing smaller, smarter and more connected technology.
General information
Firm type
other
Location
Region
North America
Country
United States
City
Danvers
Corporate office
22 Cherry Hill Drive, Danvers, Massachusetts 01923, United States
Additional offices
Aachen, Germany · Tokyo, Japan · Berlin, Germany · Halethorpe, Maryland, United States · Woburn, Massachusetts, United States
Frequently asked questions
Who runs investment decisions at Abiomed?
Abiomed is a publicly traded company (ABMD) governed by a board of directors and executive team. The CEO and CFO lead capital allocation decisions. The firm does not disclose a dedicated investment committee separate from its executive leadership.
How does Abiomed source proprietary deal flow?
Abiomed does not operate as a family office or investment firm; it is a medical device company. Its 'deal flow' consists of internal R&D projects, clinical trials, and partnerships with healthcare institutions. It does not participate in third-party venture capital or private equity investments.
Which sectors does Abiomed explicitly avoid?
Abiomed avoids all sectors outside cardiovascular and respiratory medical technology. It does not invest in software, financial services, real estate or other industries. The firm maintains a narrow focus on heart and lung recovery.
How is Abiomed related to Johnson & Johnson?
Abiomed is not directly related to Johnson & Johnson MedTech as of the latest public information. However, J&J MedTech has referenced Impella products in its press releases (per Johnson & Johnson, October 2025). No acquisition or partnership has been announced.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on investors?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: